Pharmacokinetic Modelling of Darunavir/Ritonavir Dose Reduction (800/100 to 400/100 Mg Once Daily) in a Darunavir/Ritonavir-Containing Regimen in Virologically Suppressed HIV-infected Patients: ANRS 165 DARULIGHT Sub-Study - Sorbonne Université Access content directly
Journal Articles Journal of Antimicrobial Chemotherapy Year : 2018

Pharmacokinetic Modelling of Darunavir/Ritonavir Dose Reduction (800/100 to 400/100 Mg Once Daily) in a Darunavir/Ritonavir-Containing Regimen in Virologically Suppressed HIV-infected Patients: ANRS 165 DARULIGHT Sub-Study

Dates and versions

hal-03793484 , version 1 (01-10-2022)

Identifiers

Cite

Minh P Lê, Marie-Laure Chaix, Sylvie Chevret, Julie Bertrand, François Raffi, et al.. Pharmacokinetic Modelling of Darunavir/Ritonavir Dose Reduction (800/100 to 400/100 Mg Once Daily) in a Darunavir/Ritonavir-Containing Regimen in Virologically Suppressed HIV-infected Patients: ANRS 165 DARULIGHT Sub-Study. Journal of Antimicrobial Chemotherapy, 2018, 73 (8), pp.2120--2128. ⟨10.1093/jac/dky193⟩. ⟨hal-03793484⟩
9 View
0 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More